Luye Pharma Group (HKG:2186) received approval from Japan's Ministry of Health, Labour and Welfare for its Rivastigmine twice weekly transdermal patch, according to a Monday filing with the Hong Kong bourse.
The product named Rivaluen LA Patch 25.92 mg/51.84 mg is designed to suppress the progression of dementia in mild to moderate Alzheimer's disease. The approval follows successful Phase III trials in Japan.
Luye Pharma has partnered with Japanese generics manufacturer Towa Pharmaceutical (TYO:4553) for commercialization.
Luye Pharma's shares were 2% higher in recent trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。